Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

<p>Despite the routine nature of discontinuing atrial fibrillation (AF) patients&rsquo; long-term oral anticoagulation (OAC) for procedures and &ldquo;bridging&rdquo; them with another agent, there is remarkably little data on the safety and benefit of this practice. Guidelines detailing when and how to initiate bridging therapy have been published, but data supporting why we should bridge at all are limited.<sup><span class="CharOverride-10">1</span></sup> To help fill this void, Steinberg and colleagues used a national, community-based registry of outpatients with AF (ORBIT-AF) to examine current practices around periprocedural OAC management and associated outcomes. Outcomes evaluated included rates of major bleeding, as well as myocardial infarction, stroke or systemic embolism, cause-specific hospitalization, and death within 30 days.</p>

Bridging During Anticoagulation Interruptions Is Associated with Worse Outcomes